



November 24, 2020

PeptiDream Inc.

<https://www.peptidream.com>

(Ticker Code: 4587 TSE First Section)

## PeptiDream Announces Achievement of Development Milestone in Discovery Alliance with Janssen

KANAGAWA, JAPAN – November 24<sup>th</sup>, 2020 – PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(Tokyo:4587) announced today that it has achieved a development milestone in its discovery alliance with US-based Janssen Pharmaceuticals, Inc. (“Janssen”), one of the Janssen Pharmaceutical Affiliate Companies of Johnson & Johnson. The milestone is for the identification of potential collaboration candidates meeting the pre-defined candidate criteria, representing the 2<sup>nd</sup> discovery program between the two companies for which PeptiDream has achieved this milestone. This achievement entitles PeptiDream to receive a milestone payment per the April 7, 2017 research collaboration and license agreement between both companies. PeptiDream would be potentially eligible for additional future pre-clinical and clinical development milestones, as well as royalties on future sales, as the discovery and development programs continue to advance.

### [Comment from Patrick Reid, CEO of PeptiDream Inc]

*“We are delighted to announce the achievement of this second milestone in our discovery alliance with Janssen, and we continue to be excited with the progress being made by the PeptiDream and Janssen teams across our joint discovery programs.”*

### <About PeptiDream Inc.>

PeptiDream Inc. is a public (Tokyo Stock Exchange 1<sup>st</sup> Section 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based or small molecule-based therapeutics. PeptiDream aspires to be a world leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide. For further information, please visit [www.peptidream.com](http://www.peptidream.com).

### Enquiries:

#### PeptiDream Inc.

Mie Yamazaki IR - (Kanagawa)

EMAIL: [m-yamazaki@peptidream.com](mailto:m-yamazaki@peptidream.com)